Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin with or without other LMT, both at stable dose for at least 4 weeks prior to screening visit (Week -3).~Exclusion criteria:~* Aged \<18 years or legal age of adulthood, whichever was greater.~* Participants without established CHD or CHD risk equivalent.~* LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with a history of documented cardiovascular disease.~* LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants without a history of documented cardiovascular disease.~* Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the screening visit (Week -3) or between screening to randomization visits.~* Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.~* Atorvastatin, rosuvastatin or simvastatin was not taken daily or not taken at a registered dose.~* Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg.~* Fasting serum triglycerides \>400 mg/dL (\>4.52 mmol/L) at the screening period.~The above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
- Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Type: PLACEBO_COMPARATOR): Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).